Healthcare >> Analyst Interviews >> March 10, 2017
Small-to-Midcap Biotech Companies Expected to Regain Levels
Michael Vlemmix is an Equity Analyst at KBC Securities. Mr. Vlemmix joined the research team of KBC Securities in 2016 to focus on the biotech/health care sector. He was active for there years in the startup of a medical devices spinoff company of the University of Antwerp. He graduated as a Bioengineer at the University of Ghent and Antwerp, specialized in cell and gene biotechnology and obtained an additional Master in Management at the Antwerp Management School. Profile
TWST: Would you mind telling our readers what your coverage is both in terms of the sector or subsector as well as geographically?